Renee Aguiar-Lucander
Renee Aguiar-Lucander
Chief Executive Officer
VIEW BIO
Renee Aguiar-Lucander
Renee Aguiar-Lucander
Chief Executive Officer

Born 1962. CEO since 2017.

Education: BA in Finance from Stockholm School of Economics. MBA from INSEAD.

Experience: Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services.

Other current assignments: Chairman of the board of directors of Exenta Inc. Member of the board of directors of Medcap AB (publ) and RAL Capital Ltd.

Holdings in the Company: Renée Aguiar-Lucander holds 412,000 shares in the Company, 350,000 warrants of Warrant Program 2018/2022 and 195,000 warrants of Warrant Program 2019/2022.

Frank Bringstrup
Frank Bringstrup
Vice President Regulatory Affairs
VIEW BIO
Frank Bringstrup
Frank Bringstrup
Vice President Regulatory Affairs

Born 1959. VP Regulatory Affairs since 2019.

Education: Medical education from the University of Copenhagen. He has a diploma in Managing Medical Product Innovation (MMPI) from the Copenhagen School of Economics, a diploma in business administration from Warwick University, and a post graduate specialist course in public health science from the National Board of Health, Denmark.

Experience: Frank Bringstrup has over 17 years of experience in the pharmaceutical industry within regulatory affairs and health authority interactions. Prior to joining Calliditas, he worked in various positions at Novo Nordisk A / S. He started his professional career first as a clinic doctor and then Frederiksborg County Medical Advisor.

Holding in the Company: Frank Bringstrup holds 5,000 warrants of Warrant Program 2018/2022 and 7,500 warrants of Warrant Program 2019/2022.

Fredrik Johansson
Fredrik Johansson
Chief Financial Officer
VIEW BIO
Fredrik Johansson
Fredrik Johansson
Chief Financial Officer

Born 1977. CFO since 2017.

Education: Studies in Business Law at Jönköping International Business School. Studies in Business and American law, Economics and Finance at Georgia State University, University of South Carolina and Lund University.

Experience: Fredrik Johansson has extensive experience in executive positions, primarily within telecom and software. Previously, he was CFO and COO at Birdstep Technology/ Techstep ASA, listed on the Oslo Stock Exchange, where he, among other things, was in charge of the acquisition and reversed listing of Teki Solutions. Previous CFO positions also include Phone Family, Teligent Telecom and Wayfinder Systems.

Other current assignments: Chairman of the board of directors of Truference AB. Holder of Fountainpark Consulting.

Holdings in the Company: Fredrik Johansson holds 88,250 shares in the Company, 90,000 warrants of Warrant Program 2018/2022 and 50,000 warrants of Warrant Program 2019/2022.

Krassimir Mitchev
Krassimir Mitchev
Chief Medical Officer (acting)
VIEW BIO
Krassimir Mitchev
Krassimir Mitchev
Chief Medical Officer (acting)

Born 1959. Chief Medical Officer since 2019.

Education: University of Medicine, Medical Academy, Sofia. Bulgaria

Experience: Dr Krassimir Mitchev is an MD and PhD certified in internal and pulmonary medicine. He has a broad and extensive academic and nearly 20 years pharmaceutical industry career experience including GlaxoSmithKline and UCB Pharma.  His previous position was as Therapy Area Haemophilia Medical Head at SOBI (Swedish Orphan Biovitrum) where he was responsible for leading the development and execution of the full scale global clinical and medical strategy as well as the operational activities. He joined Calliditas in March 2019.

Holding in the Company: No Holdings

Johan Häggblad
Johan Häggblad
Chief Scientific Officer
VIEW BIO
Johan Häggblad
Johan Häggblad
Chief Scientific Officer

Born 1958. VP Licensing, IP & Legal since 2017.

Education: PhD in Neurochemistry and Neurotoxicology from Stockholm University.

Experience: Johan Häggblad joined Calliditas in 2007. He has more than 25 years’ experience in the pharmaceutical industry in managerial and executive roles at Karo Bio AB (1989-1997), Pharmacia Corporation (1997-2001) and NeuroNova (2001-2007). Johan Häggblad also served as CEO in Calliditas between 2007 and 2017.

Other current assignments: Member of the board of directors of Pharmalink Oncology AS. Deputy member of the board of directors of Nefecon AB.

Holdings in the Company: Johan Häggblad holds 199,000 shares in the Company and 45,000 warrants of Warrant Program 2018/2022.

Ann-Kristin Myde
Ann-Kristin Myde
VP Head of Clinical Development & Project Management
VIEW BIO
Ann-Kristin Myde
Ann-Kristin Myde
VP Head of Clinical Development & Project Management

Born 1955. VP Project Management since 2016.

Education: Bachelor of Science in Chemistry from Stockholm University.

Experience: Ann-Kristin Myde has more than 25 years of experience from different global pharmaceutical companies, which included leading several global drug development and clinical project teams from Phase 1 to Phase 3 and launch, in senior clinical and project management positions at Kabi Pharmacia and AstraZeneca. She was also the Alliance Director in charge of a two-project collaboration with Bristol-Myers Squibb, where she managed the relationship and the strategy with the partner.

Holdings in the Company: Ann-Kristin Myde holds 73,750 shares in the Company and 3,586 warrants of Warrant Program 2018/2022.

Andrew Udell
Andrew Udell
Vice President North America Commercial
VIEW BIO
Andrew Udell
Andrew Udell
Vice President North America Commercial

Born 1970. VP North America Commercial since 2019.

Education: BSc from Lehigh University. MBA from the University of Connecticut

Experience: Andrew Udell has more than 20 years of commercial experience in the pharmaceutical industry. Before joining Calliditas, Andrew worked as Vice President of North America Commercial at NeuroDerm. Andrew began his career in the pharmaceutical industry at Purdue Pharma and held several sales and marketing positions, including responsible for the company’s brands and led a multifunctional team for a multi-billion pain medication franchise.

Holding in the Company: Andrew Udell holds 200,000 warrants of Warrant Program 2018/2022 and 20,000 warrants of Warrant Program 2019/2022.

Mikael Widell
Mikael Widell
Head of Communications and IR
VIEW BIO
Mikael Widell
Mikael Widell
Head of Communications and IR

Born 1958. Head of Communication and IR since 2017.

Education: MA in English from Lund University and studies in Economics at Lund University.

Experience: Mikael Widell has more than 30 years’ experience within communications, including journalism with 14 years within financial media, e.g. Dagens Industri, and has had different positions within in-house corporate communications, e.g. AstraZeneca, Biovitrum (Sobi) and Nordic Capital as well as strategic work as a communications advisor within financial PR and IR. Mikael is a partner and co-founder of the IR/PR firm Cord Communications.

Other current assignments: Member of the board of directors of CordCom Consultants AB. General partner of WZ Kommunikation Kommanditbolag.

Holdings in the Company: Mikael Widell does not hold any shares in the Company.

Katayoun Welin-Berger
Katayoun Welin-Berger
Vice President Operations
VIEW BIO
Katayoun Welin-Berger
Katayoun Welin-Berger
Vice President Operations

Born 1968. VP Operations since 2020.

Education: PhD in Pharmacy from Uppsala University, Sweden.

Experience: Katayoun Welin-Berger has more than 28 years of commercial experience in the pharmaceutical and biologics industry. Before joining Calliditas, Katayoun worked as Vice President of Operations at BioGaia. Katayoun began her career in the pharmaceutical industry at AstraZeneca and held several positions within both R&D and Operations.

Holding in the Company: Katayoun Welin-Berger holds 65,000 warrants of Warrant Program 2019/2022.

Shareholding in the Company as of July 15, 2019.

For more information on the warrants, see section Remuneration.